3.2 C
London
Tuesday, February 11, 2025
HomeBusinessFDA approves Novavax's enhanced COVID vaccine for autumn 2023.

FDA approves Novavax’s enhanced COVID vaccine for autumn 2023.

Date:

Related stories

What’s Next After OnlyFans? | WIRED

Access, when viewed through the lens of social media,...

DOJ Directs Prosecutors to Dismiss Corruption Charges Against NYC Mayor Eric Adams

In a recent two-page memo, acting Deputy Attorney General...

AI Investments Rose 62% to $110 Billion in 2024 Amid 12% Drop in Startup Funding

Venture capitalists are eagerly pursuing investment opportunities in startups...

Rising Dealmaking Indicates Sustained IPO Market Recovery

In the past year, the initial public offering (IPO)...

Who is Rod Blagojevich, Recently Pardoned by Trump?

On Monday, former President Donald Trump granted a full...
spot_img

The Food and Drug Administration (FDA) has authorized Novavax’s updated COVID-19 vaccine, providing Americans ages 12 and older with a third option for vaccination. Novavax’s updated shot specifically targets the XBB strains of the virus, similar to the revised formulations from Moderna and Pfizer that were approved last month. While the Moderna and Pfizer vaccines use mRNA technology, Novavax takes a different approach. This authorization allows individuals to choose a protein-based, non-mRNA option to protect against COVID-19, which has become the fourth leading cause of death in the U.S.

The dominant strains of coronavirus currently circulating in the U.S. are closely related descendants of the XBB variant, according to the Centers for Disease Control and Prevention (CDC). The FDA’s authorization is the final major regulatory hurdle before Novavax’s new vaccines can be rolled out. Previously, Novavax was only authorized as a first booster dose for those who were unwilling or unable to receive an mRNA shot. This marks the first time that many previously vaccinated individuals will be eligible to receive the protein-based Novavax vaccine.

Novavax has stated that it has “millions of doses” of its vaccine ready for shipment in the U.S. The company plans to ship these doses to various locations, including national chain drug stores and doctors’ offices, in the coming days. Shots will also be available through the federal Bridge Access and Vaccines for Children program. It is not clear why Novavax’s vaccine was authorized later than vaccines from Pfizer and Moderna, but the timing of the applications could be a possible reason. Novavax officials had previously acknowledged that their shots might take longer to update for this fall, as non-mRNA vaccines generally have a longer manufacturing time.

Source link

DMN8 Partners
DMN8 Partnershttps://salvonow.com/
DMN8 Partners utilizes a strategy of Cross Channel marketing including local search engine optimization, PPC, messaging and hyper-targeted audiences allow our clients to experience results and ROI that fuel growth and expansion in their operations. There are a lot of digital marketing options across the country but partnering with an agency that understands multiple touches on multiple platforms allows your company’s message to be seen at the perfect time, on the perfect platform, by your perfect prospect. DMN8 Partners has had years of experience growing businesses. Start growing your business today and begin DOMINATE-ing your market.